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A 45-year-old female suﬀering from severe thoracic pain was admitted to the emergency department of our hospital. Thorough
clinical examination revealed paresis of the left lower limb and sensory deﬁcit at the level of the Th4 vertebra. MRI of the thoracic
spine demonstrated a lesion at the level of Th1–Th7. Despite initial improvement following i.v. corticosteroid administration, the
patient’s clinical status deteriorated, with recurrence of myelitis and extension of the lesion to Th12. She developed paraparesis,
hyperreﬂexia and spasticity of both legs, symmetrical sensory deﬁcit below Th4, and sphincter dysfunction. Diﬀerential diagnosis
included infectious, metabolic, neoplastic/paraneoplastic, and ischemic causes as well as multiple sclerosis. NMO IgG was
found positive and led to the diagnosis of longitudinal extensive transverse myelitis (LETM) in the NMO spectrum disorders.
Administration of immunosuppressive therapy resulted in gradual improvement of the patient’s clinical status and stabilization
for ﬁve years. In the setting of LETM, patients with antiaquaporin 4 IgGs can present features of coexisting systemic involvement.
A thorough diﬀerential diagnosis is required to guide appropriate therapy.
1.Introduction
Longitudinal extensive transverse myelitis (LETM) repre-
sents a heterogeneous syndrome caused by an inﬂammatory
process of the grey and white matter of the spinal cord,
resulting in neurologic deﬁcits such as weakness, sensory
loss, and autonomic dysfunction [1]. Although its etiology
remains unknown, infectious/parainfectious, ischemic, and
metabolic causes are included in the diﬀerential diagnosis.
LETM may be associated not only with multiple sclerosis,
neuromyelitis optica (NMO) but also with systemic autoim-
mune diseases. The syndrome has rarely been reported to
occur as a ﬁrst manifestation of systemic lupus erythemato-
sus (SLE) or Sjogren’s syndrome [2–4].
Neuromyelitis optica (NMO or Devic’s disease) is a ser-
ious, idiopathic demyelinating disease of the central nervous
system (CNS) selectively attacking the spinal cord or optic
nerves [5]. Although originally considered a variation of
multiple sclerosis (MS), clinical, radiological, pathological,
and especially immunological data (detection of NMO IgG
antibody) have led to a novel deﬁnition of this clinical entity
[6]. NMO spectrum disorders include either recurrent lon-
gitudinally extensive myelitis (more than a three-vertebral-
segment spinal cord lesion seen in MRI) or recurrent optic
neuritis. NMO IgG autoantibody recognizing the water
channel aquaporin-4 represents a highly speciﬁc biomarker
for NMO as well as for NMO spectrum disorders and
is considered as an additional criterion supporting the
diagnosis [7, 8].
Early diﬀerential diagnosis of NMO from MS and syste-
mic autoimmune disorders is of vital importance as far as
therapeutic intervention is concerned, since NMO has a
poor prognosis and requires immunosuppressive and not
immunomodulatory treatment.
2.CaseReport
We present the case of a 45-year-old female complaining of
severe thoracic pain. On admission, initial clinical examina-
tion revealed impaired sensation of light touch, pain, and
senseofvibrationattheleftlowerlimb,extendingtothelevel
of Th4.2 Case Reports in Medicine
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Figure 1: Sagital T2-MRI of the spinal cord showing an extensive
enhancing thoracic lesion (Th1-Th3).
Thoracic spine MRI revealed a lesion in the spinal cord at
the levels of Th1–Th7, while an enhancing signal was noted
atthelevelsofTh1–Th3(Figure 1).BrainMRIdemonstrated
no pathological ﬁndings; visual evoked potentials were nor-
mal.
Testing for antibodies to HSV1, HSV2, VZV, CMV, EBV,
HBV, HCV, HIV in serum and cerebrospinal ﬂuid, as well as
sarcoidosis and tumor markers in serum revealed no patho-
logical values. Polymerase chain reaction in CSF for HSV1
and HSV2 was negative.
Thoracic and abdominal CT scans were not indicative
of any other pathology. Cerebrospinal ﬂuid analysis demon-
strated no lymphocytes, normal protein, and negative oligo-
clonal bands. Immunological tests revealed an ANA titer
of 1:320, while tests for anti-ENA, anti-dsDNA, anticar-
diolipin, anti-β2GPI, lupus cells, and cryoglobulins were
negative.
An initial improvement in patient’s clinical status was
noted after administration of i.v. corticosteroids (1gr
methylprednisolone for 5 days). The patient presented with
chest pain, paraparesis, hyperreﬂexia and spasticity of both
legs, symmetrical sensory deﬁcit below Th4, and sphincter
dysfunction twenty days post conclusion of oral tapering
of corticosteroid regimen. Clinical examination revealed
bilateral Babinski signs, loss of sensitivity below Th4, and left
lower extremity weakness with MRC grade 1/5 proximally
and right leg MRC grade 2/5. Visual evoked potentials and
CSF biochemical tests remained normal. However, MRI of
the thoracic spine demonstrated an extension of the preex-
isting lesion (from Th1–Th3 to Th1–Th8) and thoracic CT
scan revealed serositis with limited bilateral pleural eﬀusion.
After two weeks and while still hospitalized and receiving
oral corticosteroid tapering, the patient developed recurrent
thoracic myelitis and MRI demonstrated an extension of
the lesion to the level of Th12. The blood count revealed
leucopenia while the sedimentation rate was increased. Daily
urinary protein loss also increased slightly, at 400mg/day
(0–200mg/day). New immunological tests, performed at the
Mayo Clinic, revealed the presence of NMO-IgG antibodies.
Since our patient presented several signs of autoimmune
disease (positive ANAs, increased sedimentation rate, serosi-
tis, mild proteinuria, and gradual improvement following
corticosteroids administration), initial diﬀerential diagnosis
included autoimmune disorders (SLEs) as well as MS
and NMO. After consulting with rheumatologists, it was
decided that clinical and laboratory ﬁndings did not fulﬁll
the diagnostic criteria for SLE. Taking into account the
recurrent severe attacks of myelitis, the extensive spinal cord
lesion (Th1–Th12), the absence of oligoclonal bands, the
positive autoimmune clinical signs and indices, and the
positive NMO-IgG antibodies, it was suggested that the
patient was suﬀering from LETM of the NMO-SD type and
immunosuppressive therapy was administered.
Since i.v. cyclophosphamide is currently used to treat
patients with lupus and life-threatening neurologic diseases,
it was administered at a dose of 750mg monthly for 6
months and then every 3 months for 8 times. Uromitexan
was also administered with cyclophosphamide to prevent
hemorrhagic cystitis Oral prednisone was slowly tapered to
a daily dose of 10mg.
Our patient showed remarkable improvement two years
after initial treatment. No motor deﬁcit was detected while
sense of light touch and pain were slightly decreased below
Th4 and sense of vibration of the left leg remained im-
paired. However, three months later, while switching from
i.v. cyclophosphamide to per os immunosuppressive treat-
ment(azathioprine),sherelapsedseverely.Administrationof
corticosteroids i.v. and immunosuppressive treatment (cyc-
lophosphamide 750 mg monthly for 6 months) led to com-
plete patient’s recovery. She remains in remission for three
more years under treatment with rituximab (375mg/m2 in-
fused once per week for 4 weeks and then every two months)
CD19 cell markers are routinely monitored.
3. Discussion
Longitudinal extensive transverse myelitis (LETM) may oc-
cur as an uncommon manifestation of SLE or other autoim-
mune diseases, appearing in only 2% of patients several years
before the development of SLE [3, 4].
Diﬀerential diagnosis between the LETM that occurs in
MS and that of autoimmune disorders such as SLE or NMO
spectrum disorders is crucial, since diﬀerent therapeutic
interventions are required and interferon beta-1b treatment
may induce ﬂare-ups of both diseases [5, 6, 9, 10].
NMO IgG represents a highly speciﬁc diagnostic marker
for NMO but also for NMO spectrum disorders (NMO-
SDs), which include recurrent longitudinally extensive
myelitis or recurrent optic neuritis [7].
NMO and NMO-SD have rarely been reported as a ﬁrst
manifestation of SLE and Sjogren’s syndrome [2–4, 11, 12].
NMO and NMO-SD are rare pathological entities with
serious neurological manifestations. Concerning their asso-
ciation with autoimmune disorders, recent literature data
propose that seropositivity for NMO IgG in patients with
SLE and Sjogren’s syndrome is not an epiphenomenon,Case Reports in Medicine 3
but rather these patients possibly suﬀer from two coexis-
ting autoimmune disorders [5, 10, 13]. Pittock et al. demon-
stratedthatNMOIgGhelptodistinguishLETMasanNMO-
SD manifestation in patients with systemic autoimmune
diseases. It is noteworthy that NMO IgG was only found in
patients with SLE and coexisting LETM. On the other hand,
non-organ-speciﬁc autoantibodies were frequently found in
patients with NMO and NMO-SD [10]. Despite LETM and
NMO IgG, during admittance our patient demonstrated
clinical and biological signs of systemic involvement (serosi-
tis, leucopenia, increased ESR, and proteinuria). Never-
theless, she did not fulﬁll SLE diagnosis criteria. To our
knowledge, there is only one more case of proteinuria in
the setting of Devic’s disease. However, this was a case of
concomitant SLE [14]. In accordance with these ﬁndings,
it is recently reported that the onset of NMOSD may
precede the clinical and serological ﬁndings of systemic
autoimmunity [15]. The diﬃculty of deﬁning the underlying
disease, especially at its onset, is clearly shown in our case.
The speciﬁcity of NMO IgG for NMOSD in patients with
connective tissue diseases (CTD) was also supported by the
recent study of Janius et al. In a large study of 109 patients
with CTD, NMO IgG seropositivity was restricted to those
with NMO, LETM, or relapsing optic neuritis. The high
syndrome speciﬁcity of NMO IgG in those patients suggests
that this antibody is linked to the pathogenesis of NMO SD
and argues against being part of polyclonal B-cell activation
[15].
Patientswithoneautoimmunediseasearepredisposedto
developing another autoimmune disease [16]. Our patient
had increased ANA titer. It is reported that patients with
NMO-SD may have positive autoimmune indices. ANA and
SSA antibodies are detected in patients with NMO-SD who
do not fulﬁll diagnostic criteria of a systemic autoimmune
disease [17].
On the other hand, the presence of NMO IgG is consid-
ered as an index for the manifestation of an NMO spectrum
disorder and predicts relapse and development of deﬁnite
NMO [18]. It has been reported that coexistence of NMO
with a systemic organ- or non-organ-speciﬁc autoimmune
disorder or autoantibodies may be predictors of a poorer
prognosis [18]. The current standard for patients with lupus
and serious neurological complications is the administration
of i.v. cyclophosphamide [19]. It is recently proposed that B-
cell targeted therapy in the form of rituximab should be con-
sidered in patients with NMO and NMO-SD [20]. First- and
second-line therapy schemes for NMO and NMO SD have
been recently suggested by the task force. Azathioprine (2.5–
3mg daily) combined with oral prednisolone and rituximab
is considered as ﬁrst-line therapy while cyclophosphamide,
mitoxantrone, and mycophenolate mofetil are second line.
However, it is not clear whether NMOSD associated with
autoimmune diseases requires diﬀerent treatment strategies.
Furthermore, for rituximab, the optimal surrogate measures
and treatment intervals are unclear [21].
It is essential for clinicians to consider NMO-SD and
to initiate aggressive immunosuppression to control severe
relapses of myelitis. Even if a systemic autoimmune disease
is suspected, as in our case, NMO spectrum disorders
should be included in diﬀerential diagnosis and NMO-IgG
antibodies should be tested. The detection of such antibodies
in patients with known LTM represents a reliable marker
f o rf u t u r es e v e r er e l a p s e[ 18]. Yanagawa et al. reported
that early detection of NMO-IgG combined with proper
immunotherapy could represents the key to a good, long-
term prognosis for limited forms of NMO [22].
Patients with LETM should always be tested for NMO
IgG even if clinical and paraclinical autoimmune indices
are present since patients with NMO-SD may present
features of coexisting systemic autoimmunity. Long-term
immunosuppressive treatment should be initiated as soon
as the diagnosis is set, to prevent the attacks. Thorough
followup for NMOSD patients not fulﬁlling criteria for CTD
is mandatory to prevent severe relapses and ensure early
diagnosis of a systemic autoimmune disease. Large studies
of patients with NMO spectrum disorders may indicate
the optimal drug regimen and treatment duration to attain
complete relapse and recovery.
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